Samsara BioCapital’s EyePoint Inc EYPT Stock Holding History

Samsara BioCapital’s Portfolio EYPT Stock Details EYPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-432,000	Closed	-$3.45M	–	42
2023 Q3	$3.45M	Hold	432,000	–	–	1.06%	26
2023 Q2	$3.76M	Sell	432,000 -48,000	-10%	-$293K	0.66%	24
2023 Q1	$1.41M	Hold	480,000	–	–	0.29%	37
2022 Q4	$1.68M	Hold	480,000	–	–	0.36%	33
2022 Q3	$3.8M	Hold	480,000	–	–	0.89%	26
2022 Q2	$3.78M	Hold	480,000	–	–	1.01%	24
2022 Q1	$5.83M	Hold	480,000	–	–	1.47%	16
2021 Q4	$5.88M	Buy	480,000 +30,000	+7%	+$404K	1.14%	21
2021 Q3	$4.69M	Hold	450,000	–	–	0.74%	31
2021 Q2	$4.05M	Hold	450,000	–	–	0.5%	31
2021 Q1	$4.57M	Buy	+450,000	New	+$5.06M	0.84%	28

Other funds holding EYPT

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Samsara BioCapital's EYPT Position: Q4 2023 in Review

Samsara BioCapital sold out of EyePoint Inc (EYPT) in Q4 2023, closing a stake of 432,000 shares — an estimated $3.45M sold.

Samsara BioCapital first reported a position in EYPT in Q1 2021 and held it in 11 quarters. The position peaked at $5.88M in Q4 2021. 138 funds tracked by Wall St. Rank hold EYPT as of Q4 2023.

Samsara BioCapital reported no remaining EyePoint Inc position as of Q4 2023 after selling out during the quarter.
Samsara BioCapital sold 432,000 EyePoint Inc shares in Q4 2023, an estimated $3.45M.
Samsara BioCapital first reported a position in EyePoint Inc in Q1 2021 and held it in 11 quarters.
Samsara BioCapital's EyePoint Inc position peaked at $5.88M in Q4 2021.
138 funds tracked by Wall St. Rank held EyePoint Inc as of Q4 2023.

Based on Samsara BioCapital's 13F filing for Q4 2023, filed 14 Feb 2024.